Table 1. Concomitant associated diseases and medication at baseline.
| Survivor (n = 102) | Cardiovascular Death (n = 49) | Total (n = 151) | Sign. | |
| Age (years) | 64.3±10.2 | 72.3±9.3 | 66.9±10.6 | <0.001 |
| BMI | 26.9±3.0 | 26.3±3.3 | 26.7±3.1 | 0.318 |
| Male gender n (%) | 73 (71.6) | 28 (57.1) | 101 (66.9) | 0.097 |
| Hypertension n (%) | 76 (74.5) | 46 (93.9) | 122 (80.8) | 0.004 |
| Smoker n (%) | 80 (78.4) | 26 (53.1) | 106 (70.2) | 0.002 |
| Current smoker n (%) | 42 (41.2) | 12 (24.5) | 54 (35.8) | 0.048 |
| Diabetes mellitus n (%) | 27 (26.5) | 22 (45.8) | 49 (32.7) | 0.025 |
| Hyperlipidemia n (%) | 54 (52.9) | 24 (49) | 78 (51.7) | 0.729 |
| Hemoglobin (g/dl) | 14.2±1.5 | 13.0±1.7 | 13.8±1.6 | <0.001 |
| Homocysteine (µmol/l) | 15.0±4.8 | 16.9±4.6 | 15.5±4.8 | 0.048 |
| Total cholesterol (mg/dl) | 208.2±47.5 | 196.7±51.5 | 204.6±48.9 | 0.196 |
| HDL cholesterol (mg/dl) | 50.8±14.6 | 49.6±15.2 | 50.5±14.8 | 0.650 |
| LDL cholesterol (mg/dl) | 124.4±39.4 | 113.9±38.1 | 121.2±39.2 | 0.149 |
| Lp (a) (mg/dl) | 13.1 (9.5, 50.5) | 18.6 (10.0, 45.7) | 13.3 (9.5, 47.6) | 0.310 |
| High sensitive CRP (mg/l) | 4.0 (2.0, 8.8) | 5.5 (2.9, 8.8) | 4.2 (2.2, 8.8) | 0.140 |
| Creatinine Clearance (ml/min/1.7) | 70.6±23.5 | 56.9±26.2 | 66.1±25.1 | 0.002 |
| HbA1c (%) | 5.7 (5.4, 6.3) | 6.1 (5.5, 6.9) | 5.8 (5.4, 6.5) | 0.046 |
| Cerebrovascular disease n (%) | 52 (51.0) | 23 (46.9) | 92 (50.0) | 0.881 |
| Coronary artery disease n (%) | 20 (19.6) | 12 (24.5) | 39 (21.2) | 0.790 |
| Statin n (%) | 49 (48.0) | 24 (49.0) | 86 (46.7) | 0.643 |
| Aspirin n (%) | 75 (73.5) | 31 (63.3) | 128 (69.6) | 0.405 |
| Clopidogrel n (%) | 8 (7.8) | 6 (12.2) | 17 (9.2) | 0.682 |
| VKA n (%) | 7 (6.9) | 9 (18.4) | 19 (10.3) | 0.091 |
| Antihypertensive drug n (%) | 69 (67.6) | 43 (87.8) | 129 (70.1) | 0.001 |
BMI Body Mass Index; HDL High density lipoprotein; LDL Low density lipoprotein; Lp (a) Lipoprotein (a); HbA1c Hemoglobin A1c; VKA Vitamin K antagonists.